Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
NCT00980954
Active Not Recruiting
RATIONALE: Drugs used in chemotherapy, such as cisplatin, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether chemotherapy and radiation therapy are more effective when given with or without additional chemotherapy in treating cervical cancer. PURPOSE: This randomized phase III trial is studying chemotherapy... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/07/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +124 locations
Conditions: Cervical Cancer
Register for Updates
Acute Changes in Endothelial Function in Germ Cell Tumor Patients Treated With Cisplatin and Untreated Germ Cell Tumor Controls
NCT01453660
Active Not Recruiting
Cisplatin is one of the most common chemotherapy drugs used to treat many different cancers, including germ cell tumors (GCT). Cisplatin is very effective in treating GCT, but there are side effects. One of the possible long-term side effects of cisplatin is thought to be heart disease. The way that cisplatin causes heart disease is not well understood. One possibility is that cisplatin may damage the inside layer of blood vessels called the endothelium. The purpose of this study is to measure c... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/07/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Germ Cell Cancer
Register for Updates
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NCT02135042
Active Not Recruiting
There are two study questions we are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard concurrent chemotherapy and radiation therapy. When this standard treatment is completed, if there is no detectable EBV DNA in their plasma, then patients are randomized to either standard adjuvant cisplatin and fluorouracil chemo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/05/2024
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +214 locations
Conditions: Epstein-Barr Virus Infection, Stage II Nasopharyngeal Carcinoma, Stage III Nasopharyngeal Carcinoma, Stage IVA Nasopharyngeal Carcinoma, Stage IVB Nasopharyngeal Carcinoma
Register for Updates
Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)
NCT03515837
Completed
The purpose of this study is to evaluate the efficacy and safety of pemetrexed plus platinum chemotherapy (carboplatin or cisplatin) with or without pembrolizumab (MK-3475; KEYTRUDA®) in the treatment of adults with the following types of tyrosine kinase inhibitor (TKI)-resistant, epidermal growth factor receptor (EGFR)-mutated, metastatic non-squamous non-small cell lung cancer (NSCLC) tumors: 1) TKI-failures (including osimertinib \[TAGRISSO®\] failure) with T790M-negative mutation tumors, 2)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/05/2024
Locations: Cedars-Sinai Medical Center ( Site 0070), Los Angeles, California +157 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer
NCT01554397
Completed
The purpose of this study is to find out whether patients with cervical cancer treated with PET-guided Bone Marrow Sparing IMRT have less side effects with equal cancer control compared to standard radiation techniques (IMRT). The hypothesis is that PET-guided Bone Marrow Sparing IMRT will reduce acute hematologic and gastrointestinal toxicity and increase chemotherapy tolerance for cervical cancer patients treated with concurrent cisplatin.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/05/2024
Locations: Moores UC San Diego Cancer Center, La Jolla, California +6 locations
Conditions: Cervical Cancer
Register for Updates
Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)
NCT04989218
Terminated
This pilot trial will be used to assess the activity, safety and feasibility of doublet immunotherapy and platinum-based chemotherapy in resectable intrahepatic cholangiocarcinoma with high risk features. The hypothesis is that the combination of durvalumab/MEDI4736 and tremelimumab (doublet immunotherapy) with platinum-based chemotherapy (gemcitabine and cisplatin) will yield an objective of 52% and improve complete resection rates in intrahepatic cholangiocarcinoma. This will facilitate margin... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
11/01/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cholangiocarcinoma
Register for Updates
Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
NCT03389477
Active Not Recruiting
The purpose of this study is to evaluate the results of treating patients with HPV-unrelated head and neck squamous cell carcinoma with neoadjuvant single-agent palbociclib, followed by chemoradiation (either cisplatin + IMRT or cetuximab + IMRT depending on patient characteristics), followed by adjuvant single-agent palbociclib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
NCT02113878
Completed
This research study is evaluating a drug called buparlisib (BKM120) as a possible treatment for locally advanced head and neck squamous cell cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Carcinoma, Squamous Cell of Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Hypopharyngeal Cancer, Early Invasive Cervical Squamous Cell Carcinoma, Carcinoma of Larynx, Cancer of Nasopharynx
Register for Updates
Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers
NCT03515538
Completed
The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the duration or length of severe oral mucositis in patients with head and neck cancers. All patients in this study will receive 7 weeks of standard of care radiation therapy given with the chemotherapy agent, cisplatin. Patients in arms 1, 2 and 3 will also receive RRx-001 on different schedules.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2024
Locations: John Wayne Cancer Institute @ Providence St. John's Health Center, Santa Monica, California +11 locations
Conditions: Oral Mucositis
Register for Updates
A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer
NCT05566041
Active Not Recruiting
This Global Phase 3 study aims to find out whether RRx-001 + platinum chemotherapy is more effective than platinum chemotherapy alone in 3rd line or beyond small cell cancer.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/29/2024
Locations: H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa, Florida +1 locations
Conditions: Carcinoma, Small Cell Lung
Register for Updates
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
NCT06040970
Recruiting
This is an open-label, Phase 1 study with a dose expansion cohort of Sacituzumab Govitecan in Combination with Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer. The goal of the study is to determine the optimal dose of sacituzumab govitecan for use in combination with cisplatin for treatment of epithelial ovarian and endometrial cancers.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Icahn School of Medicine at Mount Sinai Division of Hematology and Medical Oncology, New York, New York
Conditions: Ovarian Cancer, Malignant Neoplasm of Uterus
Register for Updates
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
NCT04481204
Active Not Recruiting
This is a phase II study using the Bayesian platform design. There are three clinical stage groups of localized pancreatic cancer: resectable, borderline resectable, and locally advanced disease. Each stage group will have a defined standard of care chemotherapy regimen for a control arm, serving as a basis of comparison. Each group may have one or more experimental arms. Experimental arms may be added to the platform over time, and the effects of the experimental treatments will be tested again... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Register for Updates